Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory

53

No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.

UNKNOWN

The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply technologies for protein analysis to the detection and identification of proteins secreted by tumor cells and protein antigens that induce a humoral response in tumors. The initial targeted tumor types for the identification of potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver. The proposed studies will make heavy utilization of two-dimensional (2-D) protein analysis, of protein identification technologies and of database capabilities that have been developed by the applicant group. The objectives of this research are to 1. Identify tumor antigens that induce a humoral response; 2. Identify tumor secreted proteins and developa database; 3. Preliminarily validate the potential utilityof markers for early cancer detection. Sixty ml of bloodwill be obtained from healthy normals, and from small cell lung cancer, hepatoma, esophageal, and breast cancerpatients, and from ovarian, colon, and non-small cell lungcancer patients prior to surgical resection and six toten weeks after resection. Demographic data, sera and DNA will be used in 2-D protein analysis to identify newor altered proteins. The initial validation will be the assay of the presence or absence of a given protein in alarge sample cohort from the samples collected from thesepatients. There is no specified age range, although the diseases under study do not occur in children. No subjectswill be excluded on the basis of race or gender. Womenof child bearing age will be studied. Linkable demographicdata will be held separately from the bar-coded serum orDNA samples. Serum and DNA sample will be identifiableonly by subject identification number. Full written informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.